The U.S. Food and Drug Administration Approves Axicabtagene Ciloeucel (YESCARTA) for Diffuse Large B-Cell Lymphoma…
The Lymphoma Research Foundation (LRF) has once again been selected as an event Charity Partner for the TD Five Boro Bike Tour on May 1, 2022. Spots are limited, so don't miss your chance to sign up!
Read the Winter 2022 edition of Pulse. This issue of Pulse pays homage to family caregivers and the critical role they play in a patients' journey.
Dr. Anita Kumar is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK) and Regional Care Network Medical Site Director at MSK Basking Ridge, N.J.
Dr. Eduardo Sotomayor is embarking on a new and exciting challenge in his career that will combine his pioneering work in cancer immunology and dedication to providing quality cancer care for all patients.
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting, with more than 70 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, presenting abstracts at the conference.
Investigation into the use of chimeric antigen receptor (CAR) T cell therapies has expanded rapidly in recent years, including for hematologic malignancies. Results from several key studies were presented at the 2021 Annual ASH Meeting, which demonstrated the use of these emerging therapies in multiple lines of therapy, new disease states, and using novel constructs to enhance responses.
ASH 2021: Polatuzumab Vedotin Reduces Risk for Disease Progression in Previously Untreated Diffuse Large B-Cell Lymphoma
In the phase III POLARIX study, a team of investigators led by LRF Scientific Advisory Board (SAB) member Christopher R. Flowers, MD, MSc of the University of Texas MD Anderson Cancer Center compared the efficacy of standard R-CHOP with that of a modified drug regimen, in which vincristine was replaced with the antibody-drug conjugate polatuzumab vedotin (pola-R-CHP).
ASH 2021: BTG1 Mutation Is Associated with Aggressive Lymphomagenesis in Human and Animal Models of Diffuse Large B-Cell Lymphoma
A recurrent mutation in BTG1 is associated with a “super- competitive” B-cell phenotype in both mice and humans and may promote the development of aggressive diffuse large B-cell lymphoma (DLBCL), according to research, funded in part by LRF, presented by LRF grantee Coraline Mlynarczyk, PhD, of Weill Cornell Medicine.
ASH 2021: Minimal Residual Disease Kinetics Identified as a Predictor of Zanubrutinib-Obinutuzumab-Venetoclax Treatment Response in CLL
Minimal residual disease (MRD) kinetics were found to be predictive of achievement and durability of undetectable MRD with zanubrutinib-obinutuzumab-venetoclax (BOVen) treatment in patients with chronic lymphocytic leukemia (CLL), according to trial results presented by LRF grantee Jacob D. Soumerai, MD of Massachusetts General Hospital Cancer Center.